Meloxicam Cyclodextrin Inclusion Complex for Rapid Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and delayed pain relief due to its poor solubility, which can be addressed by forming an inclusion complex with cyclodextrins.
Innovation Solution
The formation of an inclusion complex of meloxicam with cyclodextrins, such as β-cyclodextrin, and bicarbonate, which enhances bioavailability and facilitates faster pain relief by improving solubility and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is used as a conventional NSAID, then it provides anti-inflammatory and analgesic activities, but it has poor aqueous solubility which reduces bioavailability and slows onset of pain relief
Solution Approach 1:
Cyclodextrins serve as intermediary carriers that form inclusion complexes with meloxicam. The cyclodextrin cavity encapsulates the hydrophobic meloxicam molecule, while the hydrophilic exterior of cyclodextrin interacts with aqueous environment, thereby improving solubility and bioavailability without altering the pharmacological activity of meloxicam
Solution Approach 2:
The invention changes the physical-chemical parameters of meloxicam by forming inclusion complexes. This transforms meloxicam from a poorly soluble crystalline form to a soluble complex form, increasing aqueous solubility and enabling faster dissolution and absorption, thus accelerating onset of action while maintaining therapeutic efficacy
2Speed
If the dosage of meloxicam is increased to achieve faster pain relief, then the onset of pain relief may improve, but the risk of gastrointestinal side effects increases
Solution Approach 1:
Cyclodextrins act as protective intermediaries that enhance the solubility and absorption of meloxicam. This allows achieving therapeutic plasma concentrations with lower doses, thereby reducing gastrointestinal irritation and side effects while maintaining rapid onset of pain relief through improved bioavailability
3Ease of manufacture
If conventional meloxicam formulations are used, then manufacturing is simple, but the therapeutic efficiency is limited due to poor solubility
Solution Approach 1:
The invention creates a composite pharmaceutical system consisting of cyclodextrin inclusion complexes with meloxicam. This composite material combines the drug with a solubilizing carrier, maintaining formulation simplicity while dramatically improving therapeutic efficiency through enhanced solubility, bioavailability, and consistent drug delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of cyclodextrins and bicarbonate in meloxicam formulations significantly increases bioavailability, leading to faster onset and prolonged pain relief, including for conditions like migraines and arthritis, with reduced dosages required.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
cyclodextrin compounds are also known to aggregate around a drug in a micelle-type structure
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.